We are live on ! Find out more
CASI

CASI Pharmaceuticals
CASI

Delisted

CASI was delisted on the 25th of February, 2026.

Back to rankings

30 hedge funds and large institutions have $1.92M invested in CASI Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

3% less funds holding

Funds holding: 31 → 30 (-1)

26% less capital invested

Capital invested by funds: $2.59M → $1.92M (-$670K)

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

Holders
30
Holders Change
-1
Holders Change %
-3.23%
% of All Funds
0.78%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
4
Reduced
6
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$22.4K
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$19.7K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$15.3K
4
Renaissance Technologies
Renaissance Technologies
New York
+$5.67K
5
BFA
BlackRock Fund Advisors
California
+$3.67K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$217K
2
WSCM
Wellington Shields Capital Management
New York
-$141K
3
CWM
Concert Wealth Management
California
-$45K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$25.4K
5
MC
Moors & Cabot
Massachusetts
-$20.3K

CASI Hedge Fund Activity: Q4 2015 in Review

30 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q4 2015, worth a combined $1.92M — down 26% from $2.59M a quarter earlier.

Fund positioning in CASI was balanced in Q4 2015: 5 funds opened new positions, 5 closed out, 4 added to existing stakes and 6 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $22.4K. The largest seller was Sabby Management, exiting entirely with an estimated $217K sold.

  • 30 institutional investors held CASI Pharmaceuticals (CASI) as of Q4 2015, down from 31 in Q3 2015.
  • Funds reported $1.92M of CASI Pharmaceuticals stock for Q4 2015, down 26% quarter-over-quarter.
  • 5 funds opened new CASI Pharmaceuticals positions in Q4 2015 and 5 closed out, a net change of 0 holders.
  • The largest CASI Pharmaceuticals buyer in Q4 2015 was Citadel Advisors, an estimated $22.4K added.
  • The largest CASI Pharmaceuticals seller in Q4 2015 was Sabby Management, an estimated $217K sold.

Based on aggregated 13F filings for Q4 2015.